After H.C. Wainwright and Mizuho Securities gave Sarepta Therapeutics (NASDAQ: SRPT) a Buy rating last month, the company received another Buy, this time from Needham. Analyst Chad Messer initiated coverage with a Buy rating on Sarepta Therapeutics today and set a price target of $182.00. The company’s shares closed last Monday at $142.21.
According to TipRanks.com, Messer is a 4-star analyst with an average return of 6.0% and a 44.2% success rate. Messer covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Aeglea Biotherapeutics, and Ionis Pharmaceuticals.
Currently, the analyst consensus on Sarepta Therapeutics is a Strong Buy with an average price target of $193.57, which is a 32.6% upside from current levels. In a report issued on September 15, Citigroup also maintained a Buy rating on the stock with a $190.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $175.00 and a one-year low of $73.62. Currently, Sarepta Therapeutics has an average volume of 688.4K.
Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SRPT in relation to earlier this year. Last month, Hans Lennart Rudolf Wigzell, a Director at SRPT sold 10,000 shares for a total of $1,590,044.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.
Read More on SRPT:
